What the science actually says about Mochi health (and the GLP-1 drugs they prescribe)

By Bithi Akter· Last reviewed June 2025 · 9 min read

Mochi Health prescribes semaglutide and tirzepatide to patients who qualify. The drugs work. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% average body weight loss at 68 weeks in adults with obesity. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) showed 20.9% with tirzepatide at the highest dose. Those numbers are real, and they’re the entire reason GLP-1 prescriptions tripled between 2020 and 2023.

What matters is whether Mochi’s model, its pricing, its clinical oversight, and its drug sourcing hold up to the same scrutiny.

Does Mochi health actually work, or is it just a subscription to a prescription?

Mochi connects patients to licensed providers who can prescribe GLP-1 receptor agonists. The drugs themselves have strong evidence behind them. What the platform provides on top of that is a subscription structure, a dietitian layer, and a telehealth intake. The clinical outcomes depend almost entirely on what drug you get and how well you titrate it.

Mochi charges $99/month for its membership, separate from medication costs. Brand-name semaglutide (Ozempic, Wegovy) runs $900-$1,300/month without insurance. Mochi routes most patients toward compounded semaglutide, which drops costs significantly. That’s the real value proposition: getting a prescription through a streamlined process at a price most people can afford.

The dietitian coaching is real but limited. One 15-minute video call per month doesn’t move the needle on behavior change the way the LOOK AHEAD trial (Pi-Sunyer et al., Diabetes Care, 2007) showed intensive lifestyle intervention can. It’s not nothing, but don’t sign up expecting metabolic coaching at the level of an academic weight management clinic.

What does the STEP trial data actually show, and does it apply to telehealth patients?

The STEP program ran six large trials. The most cited, STEP 1 (Wilding et al., NEJM, 2021), enrolled 1,961 adults with a BMI of 30 or above, or 27 with at least one weight-related condition. Participants received 2.4mg semaglutide weekly by injection. Average weight loss was 14.9% over 68 weeks. The placebo group lost 2.4%.

STEP 2 (Davies et al., Lancet, 2021) focused on patients with type 2 diabetes and found 9.6% weight loss at 2.4mg. Lower than STEP 1, which tells you metabolic context matters.

STEP 4 is the one people ignore. It found that stopping semaglutide caused two-thirds of the weight to come back within a year (Rubino et al., NEJM, 2021). That’s not a side effect. That’s the drug doing what it does: suppressing appetite while you take it. The weight biology reasserts itself when you stop.

Trial Drug Dose Duration Weight loss (drug) Weight loss (placebo) STEP 1 Semaglutide 2.4mg/week 68 weeks 14.9% 2.4% STEP 2 Semaglutide 2.4mg/week 68 weeks 9.6% 3.4% STEP 4 Semaglutide withdrawal , 48 weeks post-stop +6.9% regain , SURMOUNT-1 Tirzepatide 15mg/week 72 weeks 20.9% 3.1%

None of the STEP trials enrolled patients through telehealth. The participants had in-person monitoring, controlled dose escalation, and frequent follow-ups. Real-world outcomes through any telehealth platform, Mochi, Noom Med, Ro, or a compounded GLP-1 provider, will vary. Some patients do better. Many do worse because adherence drops without structured support.

How does Mochi compare to Noom, Orderly Meds, and other GLP-1 platforms?

These platforms are not the same product, though they get lumped together.

Noom started as a behavioral weight loss app. It layered in GLP-1 prescriptions (Noom Med) in 2023. Its core differentiator is psychology-based behavior change content, which has modest evidence behind it. A 2016 study in Scientific Reports (Chin et al.) found Noom’s app-based program produced 1.7 kg average weight loss in 45,971 users over 9 months, with about 78% of engaged users losing weight. That’s app-based coaching, not GLP-1 combined with coaching. Noom Med’s combined model hasn’t published independent trial data yet.

Orderly Meds operates on a lower-touch model, closer to a prescription pipeline than a wellness program. Pricing is more transparent upfront. Orderly Meds doesn’t advertise a coaching layer the way Mochi does. If you want the drug and a provider, and you don’t want to pay for coaching you won’t use, that model is cheaper.

Mochi sits in the middle: more clinical-seeming than Orderly Meds, less behavior-focused than Noom. The dietitian calls are a genuine differentiator if you use them. Most subscribers don’t.

The honest comparison comes down to three things: drug sourcing, price per month, and how much provider access you actually get when something goes wrong.

Platform Monthly membership Drug cost (compounded) Coaching layer Provider access Mochi Health $99 Varies by pharmacy Dietitian (1x/month) Async + video Noom Med $70 (app) + prescription fee Varies Psychology app + coach Async Orderly Meds Lower/no membership Varies Minimal Async FormBlends No membership fee listed Compounded, 503B-sourced , Telehealth provider

Prices shift constantly in this market. Verify current pricing directly with each platform before making a decision.

Is compounded semaglutide from Mochi the same drug as Wegovy?

No. It contains the same active ingredient, semaglutide, but it’s not the same product.

Wegovy is an FDA-approved drug manufactured by Novo Nordisk under specific conditions, in specific formulations, with specific excipients. Compounded semaglutide is produced by a compounding pharmacy, either a 503A (patient-specific, requires a prescription) or a 503B (outsourcing facility, produces larger batches under FDA oversight but without full approval). The FDA does not approve compounded drugs. It does, however, regulate 503B facilities under the Drug Quality and Security Act.

The FDA added semaglutide to its drug shortage list in 2022, which legally permitted compounding pharmacies to produce it. As of early 2025, the FDA declared the shortage resolved and began enforcement actions against compounders. That legal status is still moving, and platforms that source from 503B pharmacies, including some compounded GLP-1 providers, are operating in a tighter regulatory window than they were 18 months ago.

If you’re using a compounded GLP-1 through any platform right now, verify that your pharmacy is 503B-registered. The FDA maintains a public database. A 503A pharmacy compounding semaglutide for general sale is not operating legally under current guidance.

I use a 503B-sourced compounded GLP-1 through a telehealth provider because my PCP wouldn’t prescribe Wegovy, my insurance wouldn’t cover it, and $1,100/month wasn’t happening. I’ve gone from 247 to 209 lbs in six months. That’s roughly 15.4% body weight loss, which tracks with the STEP 1 average. The nausea in month one was real. Starting at 0.25mg and titrating slowly helped.

What are the actual side effects, and how common are they?

The STEP 1 trial reported that 44% of patients on semaglutide experienced nausea, versus 16% on placebo. Vomiting affected 24.5% on drug versus 6.8% on placebo. Diarrhea: 29.7% versus 15.9%. Most of these were rated mild to moderate and declined after the first 12–16 weeks as the body adjusted.

More serious: pancreatitis occurred in 0.3% of semaglutide patients in STEP 1. Gallbladder disease, including gallstones, showed up at higher rates in drug groups across multiple STEP trials. The FDA label for Wegovy carries a warning about thyroid C-cell tumors based on rodent data; the human risk hasn’t been established but can’t be ruled out.

Muscle loss is a real concern. A 2023 analysis by Wilding et al. in Obesity Reviews found that GLP-1 agonists produce fat-free mass loss alongside fat loss, ranging from 25–39% of total weight lost being lean mass depending on the study. Resistance training and adequate protein intake (at least 1.2–1.6g/kg of body weight per day, per the PROT-AGE study group recommendations) can partially offset this. No platform’s coaching adequately addresses this in my experience.

Should you use Mochi, or is there a better option?

Mochi is a real platform with real prescribers and real drugs. It’s not a scam. The clinical evidence for the medications it prescribes is strong. Its membership fee is reasonable if you use the dietitian access. It’s not the right choice if you want the lowest possible monthly cost, or if you want more intensive clinical oversight than async messaging provides.

The better question is what you need. If you’ve already done the research, know you want compounded semaglutide or tirzepatide, and want a streamlined telehealth pathway without paying for coaching you won’t use, a leaner compounded GLP-1 platform may be a better fit and cost less.

If you want behavior change support alongside the medication, Noom Med’s app layer is more developed than Mochi’s, though it hasn’t published combined outcome data.

If your PCP will prescribe and your insurance covers it, use that. Brand-name semaglutide through a physician with in-person monitoring is still the gold standard from a clinical oversight standpoint.

The drugs work. The platform mostly just determines how you access them, how much you pay, and who you can call when something feels wrong.

Frequently asked questions

How much does Mochi health cost per month?

Mochi charges $99/month for membership. Medication costs are separate and vary by pharmacy. Compounded semaglutide through Mochi-affiliated pharmacies has ranged from $150-$350/month depending on dose and sourcing. That’s far below the $900+ cash price for brand Wegovy. Verify current pricing directly with Mochi before signing up.

Is compounded semaglutide legal in 2025?

The FDA declared the semaglutide shortage resolved in early 2025 and moved to restrict compounding. As of mid-2025, 503B outsourcing facilities can still compound under certain conditions, but 503A pharmacies producing semaglutide for general dispensing face enforcement risk. The legal landscape is changing fast. Check the FDA’s current shortage list and 503B database before committing.

Does Mochi require in-person visits?

No. Mochi operates entirely via telehealth. Intake, prescribing, and follow-ups happen through video or async messaging. There are no in-person requirements. That’s the model’s main advantage and its main limitation: convenient, but no in-person physical exam.

How does Mochi compare to Noom Med?

Mochi has a dietitian coaching layer and a clinical focus. Noom Med has a more developed behavioral app and psychology-based content but its combined GLP-1 plus coaching outcome data hasn’t been published. Both prescribe compounded or brand GLP-1s depending on the patient. Noom’s app engagement is higher; Mochi’s clinical framing is stronger.

Will the weight come back when I stop?

Most of it, yes. STEP 4 (Rubino et al., NEJM, 2021) showed that patients who stopped semaglutide after 20 weeks regained about two-thirds of their lost weight within 48 weeks. This is consistent across GLP-1 trials. It reflects the chronic nature of obesity, not a failure of willpower. Most patients who get meaningful benefit from these drugs need to stay on them long-term.

What is a 503B pharmacy and why does it matter?

A 503B outsourcing facility is a compounding pharmacy registered with the FDA and subject to current Good Manufacturing Practice (cGMP) standards. Drugs from 503B facilities have more quality oversight than those from standard 503A pharmacies. If you’re using compounded semaglutide from any platform, including Mochi, ask specifically whether your medication comes from a 503B-registered facility. The FDA maintains a public list at fda.gov.

Is Mochi health available in all states?

No. Telehealth prescribing laws vary by state. Mochi is not available in all 50 states, and some states have specific restrictions on GLP-1 telehealth prescribing. Check Mochi’s current availability map before starting the intake process.

Sources

1. Wilding, J.P.H. et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Jastreboff, A.M. et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Rubino, D. et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2307185
4. Davies, M. et al. “Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2).” Lancet, 2021. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext
5. Chin, S.O. et al. “Successful weight reduction and maintenance by using a smartphone application in those with overweight and obesity.” Scientific Reports, 2016. https://www.nature.com/articles/srep34563
6. Wilding, J.P.H. et al. “Cardiovascular, metabolic and body composition changes with semaglutide.” Obesity Reviews, 2023.
7. U.S. Food and Drug Administration. “Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.” FDA.gov. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
8. U.S. Food and Drug Administration. “Human Drug Compounding.” FDA.gov. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding